| 摘要 |
The present invention relates to the intermittent administration of a growth hormone secretagogue to a patient. The hormone secretagogue is, for example, 2-amino- N-[2-(3a-(R)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro- pyrazolo[4,3-c]pyridin-5-yl)-1-(R)-benzyloxymethyl-2-oxo- ethyl]-isobutyramide or a pharmaceutically acceptable salt or prodrug thereof, or a pharmaceutically acceptable salt of the prodrug. The growth hormone secretagogue may be taken, for example, every 2, 3 or 4 days. By this way, unwanted effects associated with daily administration of the growth hormone secretagogue may be ameliorated.
|
